Disease · MONDO_0005580

esophageal squamous cell carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. esophageal squamous cell carcinoma. Diseases, record MONDO_0005580. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005580

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: esophageal squamous cell carcinoma; Open Targets
Open Targets ID: MONDO_0005580; Open Targets
Other names: ESCC, esophageal epidermoid carcinoma, esophageal scc, esophageal squamous cell cancer, esophagus scc, esophagus squamous cell carcinoma, oesophagus scc, scc of esophagus, scc of the esophagus, scc of the oesophagus, squamous cell car. - esophagus, squamous cell car. - oesophagus, squamous cell carcinoma of esophagus, squamous cell carcinoma of oesophagus, squamous cell carcinoma of the esophagus, squamous cell carcinoma of the oesophagus; Open Targets
Disease Ontology: DOID:3748; Disease Ontology
MeSH: C562729; MeSH
MeSH: D000077277; MeSH
NCI Thesaurus: C4024; NCI Thesaurus
Orphanet: ORPHA:99977; Orphanet
Highest stage of its drugs: Approval, for 3 of its 143 drugs, from EMA Human Drugs and FDA; Open Targets

Drugs143

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TISLELIZUMAB	CHEMBL4297840	Antibody	Approval	EMA Human Drugs and FDA	53	51	47	Drugs and targets
TORIPALIMAB	CHEMBL4297843	Antibody	Approval	EMA Human Drugs	44	42	40	Drugs and targets
SERPLULIMAB	CHEMBL4594550	Antibody	Approval	EMA Human Drugs	9	8	8	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	178	178	166	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	134	134	134	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 3	ClinicalTrials.gov	61	61	60	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 3	ClinicalTrials.gov	52	52	51	Drugs and targets
CAMRELIZUMAB	CHEMBL4297715	Antibody	Phase 3	ClinicalTrials.gov	48	48	45	Drugs and targets
SINTILIMAB	CHEMBL4297829	Antibody	Phase 3	ClinicalTrials.gov	35	35	33	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 3	ClinicalTrials.gov	34	34	32	Drugs and targets

1 to 10 of 143

See all 143 drugs

Targets148

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	15	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Approval	https://conductscience.org/library/genes/5133	Drugs and targets
EGFR	Epidermal growth factor receptor	13	Epidermal growth factor receptor erbB1 antagonist; Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/1956	Drugs and targets
KDR	Vascular endothelial growth factor receptor	10	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
CD274	Programmed cell death 1 ligand 1	9	Programmed cell death 1 ligand 1 binding agent; Programmed cell death 1 ligand 1 inhibitor; Programmed cell death 1 ligand 1 other	Phase 3	https://conductscience.org/library/genes/29126	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	6	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2324	Drugs and targets
ERBB2	Epidermal growth factor receptor	5	Epidermal growth factor receptor inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor	Phase 2	https://conductscience.org/library/genes/2064	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	5	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2321	Drugs and targets
CTLA4	Cytotoxic T-lymphocyte protein 4	4	Cytotoxic T-lymphocyte protein 4 inhibitor	Phase 3	https://conductscience.org/library/genes/1493	Drugs and targets
TUBA1A	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets

1 to 10 of 148

See all 148 targets

Trials473

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 12 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03143153	A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin	Phase 3	970	2022-03-02	Various Advanced Cancer	CISPLATIN, FLUOROURACIL, IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT03189719	First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)	Phase 3	749	2021-07-06	Esophageal Neoplasms	CISPLATIN, FLUOROURACIL, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03783442	A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma	Phase 3	649	2023-11-07	Esophageal Squamous Cell Carcinoma (ESCC)	CAPECITABINE, CISPLATIN, FLUOROURACIL, OXALIPLATIN, PACLITAXEL, TISLELIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02564263	Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)	Phase 3	628	2019-11-20	Esophageal Carcinoma, Esophagogastric Junction Carcinoma	DOCETAXEL, IRINOTECAN, PACLITAXEL, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03829969	Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma	Phase 3	514	2024-05-02	Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy	TORIPALIMAB	Its record names the disease	ClinicalTrials.gov
NCT03430843	A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma	Phase 3	512	2023-12-29	Esophageal Squamous Cell Carcinoma (ESCC)	DOCETAXEL, IRINOTECAN, PACLITAXEL, TISLELIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03099382	Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer	Phase 3	457	2024-01-22	Esophageal Carcinoma	CAMRELIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02569242	Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer	Phase 3	419	2022-01-14	Esophageal Cancer	DOCETAXEL, NIVOLUMAB, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT03386721	Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors	Phase 2	256	2023-02-21	Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers	ATEZOLIZUMAB, SIMLUKAFUSP ALFA	Its record names the disease	ClinicalTrials.gov
NCT04032704	A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors	Phase 2	205	2025-03-10	Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma	LADIRATUZUMAB VEDOTIN, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 473

See all 473 trials

Comparisons in its trials33

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Pembrolizumab + SOC vs Placebo + SOC: deaths from any cause	331 of 373	363 of 376	749	NCT03189719	Trial comparisons
Pembrolizumab + SOC vs Placebo + SOC: Number of Participants With an Adverse Event (AE)	370 of 370	368 of 370	740	NCT03189719	Trial comparisons
Pembrolizumab + SOC vs Placebo + SOC: Number of Participants Discontinuing Study Treatment Due to an AE	90 of 370	74 of 370	740	NCT03189719	Trial comparisons
Pembrolizumab + SOC vs Placebo + SOC: serious adverse events	207 of 370	204 of 370	740	NCT03189719	Trial comparisons
Tislelizumab + Chemotherapy vs Placebo + Chemotherapy: deaths from any cause	252 of 326	268 of 323	649	NCT03783442	Trial comparisons
Tislelizumab + Chemotherapy vs Placebo + Chemotherapy: serious adverse events	160 of 324	128 of 321	645	NCT03783442	Trial comparisons
Pembrolizumab vs Chemotherapy: Number of Participants Experiencing an Adverse Event (AE)	301 of 314	288 of 296	610	NCT02564263	Trial comparisons
Pembrolizumab vs Chemotherapy: Number of Participants Discontinuing Study Treatment Due an Adverse Event (AE)	40 of 314	42 of 296	610	NCT02564263	Trial comparisons
Toripalimab vs Placebo: PFS Assessed Per irRECIST	128 of 257	160 of 257	514	NCT03829969	Trial comparisons
Toripalimab vs Placebo: ORR Assessed Per irRECIST	180 of 257	136 of 257	514	NCT03829969	Trial comparisons

1 to 10 of 33

See all 33 comparisons in its trials

Papers from its trials255

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39972105	RESULT	1	PubMed
38710003	RESULT	2	PubMed
37852261	RESULT	1	PubMed
37797632	RESULT	1	PubMed
37195667	RESULT	2	PubMed
37080222	RESULT	1	PubMed
36990609	RESULT	4	PubMed
35442766	RESULT	1	PubMed
35419831	RESULT	1	PubMed
35108470	RESULT	2	PubMed

1 to 10 of 255

See all 255 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005580

GET https://conductscience.org/api/diseases/v1/MONDO_0005580/drugs?page=2

API reference For AI assistants